COMPOUNDS AND USES THEREOF - Senolytic Compounds for Aging Treatment
Summary
The USPTO published patent application US20260097022A1 for senolytic compounds and methods for treating aging-related conditions. The application covers screening of 2,352 compounds for senolytic activity and trained neural networks to predict activity across over 800,000 molecules. Compounds disclosed bind to Bcl-2 proteins and reduce senescent cell burden. Application filed October 2, 2025; published April 9, 2026.
What changed
The USPTO published patent application US20260097022A1 titled 'COMPOUNDS AND USES THEREOF' for senolytic compounds targeting senescent cells in aging treatment. The application discloses methods of screening 2,352 compounds for senolytic activity, machine learning algorithms trained to predict senolytic activity across 800,000+ molecules, and molecular docking simulations demonstrating Bcl-2 protein binding. Compounds are described as selectively targeting senescent cells with favorable medicinal chemistry properties.
Affected parties including pharmaceutical companies, biotechnology firms, and researchers in anti-aging therapeutics should monitor this application for competitive implications. The claimed compounds and AI prediction methods may affect freedom-to-operate analyses for existing senolytic drug development programs. This publication does not grant patent rights; the application remains under examination.
What to do next
- Monitor for patent grant status
Archived snapshot
Apr 11, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOUNDS AND USES THEREOF
Application US20260097022A1 Kind: A1 Apr 09, 2026
Inventors
Felix WONG, Satotaka OMORI
Abstract
The accumulation of senescent cells is associated with aging, inflammation, and cellular dysfunction. Senolytic drugs can alleviate age-related comorbidities by selectively killing senescent cells. Described herein is a screen of 2,352 compounds for senolytic activity in a model of senescence and trained neural networks to predict the senolytic activities of >800,000 molecules. Methods, systems, and algorithms of the disclosure can enrich for structurally diverse compounds with senolytic activity. Compounds of the disclosure can comprise drug-like compounds which selectively target senescent cells across different senescence models, with more favorable medicinal chemistry properties than, and selectivity comparable to, those of a documented senolytics. Molecular docking simulations of compound binding to several senolytic protein targets, combined with time-resolved fluorescence energy transfer experiments, indicate that these compounds act in part by inhibiting Bcl-2, a regulator of cellular apoptosis. Compounds of the present disclosure can decrease senescent cell burden and mRNA expression of senescence-associated genes.
CPC Classifications
A61K 31/426 A61K 9/006 A61P 43/00 C07D 277/74
Filing Date
2025-10-02
Application No.
19348275
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.